
Earnings Insights
AI-generated analysis of quarterly earnings, concall highlights, and financial performance across Indian listed companies.
How to use these insights
Each article is built from earnings call transcripts and structured rank signals. Start with the latest summary, then open the stock page for the full company view, the concall page for quarter-by-quarter commentary, and the rankings dashboard to compare peers.
Rolex Rings Q4 FY25 earnings call: Revenue & Margins | Arthneeti
Q4 FY25
Incremental orders worth ~175 crore likely to start contributing from Q2 FY26, boosting revenues (Hiren, 00:44:45). Key concall takeaways from Rolex Rings…
5 Aug 2026
Rolex Rings Q3 FY25 earnings call: Revenue & Margins | Arthneeti
Q3 FY25
Total incremental business of approximately ₹175 crores is planned for FY 26 from new customers and programs. Key concall takeaways from Rolex Rings Ltd's Q3…
5 Aug 2026
Alivus Life Sciences Q3 FY26 earnings call: Revenue & Margins | Arthneeti
Q3 FY26
Mature molecules show stable volumes with 2-3% growth, while newer launches and upcoming patent expiries offer significant volume expansion opportunities. Key…
5 Aug 2026
Alivus Life Sciences Q4 FY25 earnings call: Revenue & Margins | Arthneeti
Q4 FY25
Earnings:** PAT margin for FY’25 stood at 20.3%, with Q4 FY’25 PAT margin at 21.8%, indicating steady profit growth. Key concall takeaways from Alivus Life…
5 Aug 2026
Alivus Life Sciences Q3 FY25 earnings call: Revenue & Margins | Arthneeti
Q3 FY25
Volume growth for Q3 FY'25 was strong at about 18%, despite a ~6% price erosion. Key concall takeaways from Alivus Life Sciences Ltd's Q3 FY25 earnings call…
5 Aug 2026
Tatva Chintan Pharma Chem Q2 FY26 earnings call: Revenue & Margins | Arthneeti
Q2 FY26
Goods in transit for the PASC (Phase Transfer Catalysts) segment have increased from INR16-17 crores last quarter to INR26 crores this quarter, reflecting an…
5 Aug 2026
Tatva Chintan Pharma Chem Q1 FY26 earnings call: Revenue & Margins | Arthneeti
Q1 FY26
Capex plan for FY '26: approximately INR 110 crores to support growth and new product lines. Key concall takeaways from Tatva Chintan Pharma Chem Ltd's Q1 FY26…
5 Aug 2026
Tatva Chintan Pharma Chem Q3 FY25 earnings call: Revenue & Margins | Arthneeti
Q3 FY25
Revenue potential could surpass INR 900 crores with existing and upcoming capacities by 2026. Key concall takeaways from Tatva Chintan Pharma Chem Ltd's Q3…
5 Aug 2026
GMR Airports Q3 FY25 earnings call: Revenue & Margins | Arthneeti
Q3 FY25
Robust traffic growth despite aircraft supply constraints, with aircraft operating above 85-90% load factors. Key concall takeaways from GMR Airports Ltd's Q3…
5 Aug 2026
Clean Science & Technology Q2 FY26 earnings call: Revenue & Margins | Arthneeti
Q2 FY26
Domestic market (mainly HALS) grew 13% in H1 FY26; still room to expand customer base with 70-75% capacity utilization for food-grade antioxidants. Key concall…
5 Aug 2026
G R Infraprojects Q2 FY26 earnings call: Revenue & Margins | Arthneeti
Q2 FY26
2,800 crores EPC value pending. Key concall takeaways from G R Infraprojects's Q2 FY26 earnings call — and how it ranks against sector peers.
5 Aug 2026
G R Infraprojects Q4 FY25 earnings call: Revenue & Margins | Arthneeti
Q4 FY25
As of Q4 FY25, G R Infraprojects Limited's order book stood at INR 24,346 crores. Key concall takeaways from G R Infraprojects Ltd's Q4 FY25 earnings call…
5 Aug 2026
Krishna Institute of Medical Sciences Q1 FY26 earnings call: Revenue & Margins | Arthneeti
Q1 FY26
Capacity utilization and bed additions will drive volume increase, although new capacity commissioning will take 4-5 years to reach 70% occupancy levels. Key…
5 Aug 2026
Krishna Institute of Medical Sciences Q3 FY25 earnings call: Revenue & Margins | Arthneeti
Q3 FY25
. Key concall takeaways from Krishna Institute of Medical Sciences Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.
5 Aug 2026
Dodla Dairy Q3 FY26 earnings call: Revenue & Margins | Arthneeti
Q3 FY26
Value-Added Products (VAP)**: Standalone VAP share has increased from 23% to 25% despite tough summer, indicating steady but moderate growth. Key concall…
5 Aug 2026
Shyam Metalics & Energy Q1 FY26 earnings call: Revenue & Margins | Arthneeti
Q1 FY26
Strong operational performance and volume growth of 32% year-on-year indicating good demand traction. Key concall takeaways from Shyam Metalics & Energy Ltd's…
5 Aug 2026
Shyam Metalics & Energy Q3 FY25 earnings call: Revenue & Margins | Arthneeti
Q3 FY25
Strategic capex is planned with minimum IRR of 17% to 20%, ensuring volume, margin, and shareholder value growth. Key concall takeaways from Shyam Metalics &…
5 Aug 2026
Dodla Dairy Q1 FY26 earnings call: Revenue & Margins | Arthneeti
Q1 FY26
Volume growth in India liquid milk is about 3%, Africa milk volume grew by 19% year-on-year. Key concall takeaways from Dodla Dairy Ltd's Q1 FY26 earnings call…
5 Aug 2026
Dodla Dairy Q3 FY25 earnings call: Revenue & Margins | Arthneeti
Q3 FY25
EBITDA margins are around 7-9% for key products like ghee; overall EBITDA margins are stable at about 10.6% for Q3 FY25. Key concall takeaways from Dodla Dairy…
5 Aug 2026
Powergrid Infrastructure Investment Trust Q3 FY26 earnings call: Revenue & Margins | Arthneeti
Q3 FY26
Additionally, the Brahmaputra Basin transmission system investment is ₹6.43 lakh crores, with ₹1.91 lakh crores planned up to 2035 and the rest beyond 2035…
5 Aug 2026
Arthneeti Pro · Annual
Every earnings call this season,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access